Skip to main content
Clinical Trials/NCT06895785
NCT06895785RecruitingNot Applicable

Exalt Single-use Duodenoscope Vs Reusable Scope, a Randomized Controlled Trial

Rush University Medical Center1 site in 1 country100 target enrollmentStarted: February 21, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
100
Locations
1
Primary Endpoint
Number of attempts required to achieve successful cannulation of the desired duct

Study Overview

Brief Summary

This randomized controlled trial (RCT) is designed to evaluate the new generation Exalt Model disposable duodenoscope compared to the reusable scope in terms of feasibility, ease of use, adverse events, number of crossover events, and infection rates.

Detailed Description

To ensure a safe and high-quality endoscopy, there are multiple disinfection protocols for endoscopes. Side-viewing duodenoscopes with an adjustable accessory device (elevator) contain potential blind spots for debris and bacteria that require specialized cleaning and disinfection methods beyond standard protocols for other endoscopes. It is thought that the duodenoscope's design, persistent postprocedural microbial contamination and biofilm formation make it more prone to cross-contamination5. Gromski et al, found there are documented pathogenic transmissions, which led to harm in multiple patients and centers3. Infection control was likely related to two major components, reusable duodenoscopes and procedural factors related to how the reusable duodenoscopes were reprocessed3. Multidrug-resistant organisms, such as carbapenem-resistant Enterobacteriaceae, that were associated with reusable duodenoscopes lead the FDA to mandate the transition to improved cleaning and disinfection methods or single-use platforms to eliminate infection transmission. One such single-use platform is the Exalt Model D (Boston Scientific, Marlboro, MA), which received FDA approval in 2020 for use of single-use duodenoscopes. Early iterations of the Exalt were used on a case-by-case basis per institution-specific protocols, mainly due to the learning curve involved with using the scope. A new version of Exalt has been released to market in 2023 with modifications that may make it more feasible to use in all settings requiring a duodenoscope. This randomized controlled trial (RCT) is designed to evaluate the new generation Exalt Model disposable duodenoscope compared to the reusable scope in terms of feasibility, ease of use, adverse events, number of crossover events, and infection rates.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
Single (Participant)

Eligibility Criteria

Ages
19 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •All patients > 18 years old who have biliary or pancreatic duct disorder, based on clinical symptoms and radiological findings at CT or magnetic resonance cholangiopancreatography
  • •Native papilla

Exclusion Criteria

  • •Patients with altered pancreaticobiliary anatomy
  • •Pregnancy
  • •Patients with percutaneous transhepatic biliary drainage
  • •Prior history of ERCP
  • •Inability to provide informed consent

Arms & Interventions

Exalt Model D

Experimental

Exalt Model D single use duodenoscope will be used for ERCP

Intervention: Exalt Model D (Device)

Standard Reusable

Active Comparator

Standard reusable model of duodenoscope will be used for ERCP

Intervention: Reusable (Device)

Outcomes

Primary Outcomes

Number of attempts required to achieve successful cannulation of the desired duct

Time Frame: From the time of the ERCP to 7 days post-ERCP per standard of care

Measure and compare the total number of attempts required to achieve successful cannulation of the desired duct.

Secondary Outcomes

  • Crossover single to reusable(From the start of the ERCP to the end of procedure)
  • Use of advanced cannulation techniques(From the start of the ERCP to the end of procedure)
  • Performance on ERCP maneuvers(From the start of the ERCP to the end of procedure)
  • Adverse events(From the completion of the ERCP to 7 days post-ERCP per standard of care)
  • Endoscopist-determined ease of use(From the start of the ERCP to the end of procedure)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Neal Ambrish Mehta

Assistant Professor

Rush University Medical Center

Study Sites (1)

Loading locations...

Similar Trials

Exalt Single-use Duodenoscope Vs Reusable... | Clinical Trial